Q4 2024 Earnings Estimate for Elanco Animal Health Incorporated Issued By William Blair (NYSE:ELAN)

Elanco Animal Health Incorporated (NYSE:ELAN) – Stock analysts at William Blair raised their Q4 2024 EPS estimates for shares of Elanco Animal Health in a note issued to investors on Thursday, October 10th. William Blair analyst B. Vazquez now expects that the company will post earnings of $0.18 per share for the quarter, up from their previous estimate of $0.17. The consensus estimate for Elanco Animal Health’s current full-year earnings is $0.91 per share. William Blair also issued estimates for Elanco Animal Health’s Q1 2025 earnings at $0.32 EPS, Q3 2025 earnings at $0.14 EPS, Q1 2026 earnings at $0.36 EPS, Q2 2026 earnings at $0.32 EPS and Q3 2026 earnings at $0.18 EPS.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings results on Thursday, August 8th. The company reported $0.30 EPS for the quarter, beating the consensus estimate of $0.24 by $0.06. The business had revenue of $1.18 billion for the quarter, compared to analyst estimates of $1.15 billion. Elanco Animal Health had a positive return on equity of 7.29% and a negative net margin of 27.94%. Elanco Animal Health’s quarterly revenue was up 12.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.18 EPS.

A number of other brokerages have also recently weighed in on ELAN. Piper Sandler cut their price objective on shares of Elanco Animal Health from $19.00 to $16.00 and set a “neutral” rating on the stock in a report on Monday, July 1st. Barclays lifted their price objective on shares of Elanco Animal Health from $21.00 to $22.00 and gave the company an “overweight” rating in a report on Monday, September 23rd. Stifel Nicolaus reissued a “buy” rating and issued a $20.00 target price on shares of Elanco Animal Health in a report on Thursday, September 19th. Finally, Morgan Stanley cut Elanco Animal Health from an “overweight” rating to an “equal weight” rating and reduced their price objective for the stock from $17.00 to $15.00 in a research note on Thursday, September 19th. One analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $17.43.

Elanco Animal Health Stock Performance

ELAN opened at $14.37 on Monday. Elanco Animal Health has a 1-year low of $8.52 and a 1-year high of $18.80. The company’s fifty day moving average price is $14.38 and its two-hundred day moving average price is $14.97. The company has a current ratio of 2.93, a quick ratio of 1.75 and a debt-to-equity ratio of 0.92. The company has a market cap of $7.10 billion, a price-to-earnings ratio of -5.42, a PEG ratio of 1.53 and a beta of 1.40.

Institutional Trading of Elanco Animal Health

Several institutional investors have recently made changes to their positions in the company. Benjamin F. Edwards & Company Inc. raised its holdings in Elanco Animal Health by 337.7% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 1,764 shares of the company’s stock worth $26,000 after purchasing an additional 1,361 shares in the last quarter. ORG Wealth Partners LLC bought a new position in shares of Elanco Animal Health during the third quarter worth about $29,000. ORG Partners LLC bought a new stake in Elanco Animal Health in the 2nd quarter valued at about $31,000. nVerses Capital LLC acquired a new position in Elanco Animal Health during the second quarter worth about $32,000. Finally, Quarry LP purchased a new stake in shares of Elanco Animal Health during the second quarter valued at $40,000. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Insiders Place Their Bets

In other Elanco Animal Health news, Director Michael J. Harrington bought 3,500 shares of Elanco Animal Health stock in a transaction that occurred on Thursday, August 22nd. The stock was acquired at an average cost of $14.85 per share, for a total transaction of $51,975.00. Following the completion of the transaction, the director now directly owns 81,094 shares in the company, valued at $1,204,245.90. This represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. In related news, CEO Jeffrey N. Simmons bought 100,000 shares of Elanco Animal Health stock in a transaction dated Monday, August 12th. The shares were acquired at an average cost of $13.01 per share, with a total value of $1,301,000.00. Following the completion of the transaction, the chief executive officer now owns 145,000 shares in the company, valued at $1,886,450. The trade was a 200.00 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Michael J. Harrington bought 3,500 shares of Elanco Animal Health stock in a transaction that occurred on Thursday, August 22nd. The shares were acquired at an average cost of $14.85 per share, for a total transaction of $51,975.00. Following the completion of the transaction, the director now directly owns 81,094 shares in the company, valued at $1,204,245.90. This represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 0.57% of the company’s stock.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.